Molecular Partners AG
NASDAQ: MOLN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Patrick Amstutz
- Employees
- 158
- Headquarters
- Schlieren, Switzerland
- IPO year
- 2021
- Market cap
- $142.5M
- Website
- https://www.molecularpartners.com
Loading MOLN…
Loading profile data…Frequently asked questions about MOLN
What does Molecular Partners AG (MOLN) do?
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, and commercialization of innovative therapeutic proteins. The firm's pipeline includes a range of product candidates, many of which utilize its proprietary DARPin® technology. Key developments include Abicipar, a DARPin...
Where does MOLN trade?
Molecular Partners AG (MOLN) trades on the NASDAQ Global Select.
What sector is MOLN in?
Molecular Partners AG (MOLN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Molecular Partners AG?
Patrick Amstutz is the chief executive officer of Molecular Partners AG (MOLN).
Where is Molecular Partners AG headquartered?
Molecular Partners AG is headquartered in Switzerland.
Does MOLN pay a dividend?
Molecular Partners AG (MOLN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MOLN go public?
Molecular Partners AG (MOLN) completed its initial public offering in 2021.
Is MOLN an ADR?
Yes — MOLN is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Molecular Partners AG reporting and dividends follow the underlying issuer.